Company Encyclopedia
View More
name
Astria Therapeutics
ATXS.US
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc.
1.946 T
ATXS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking218/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-64.56%E
    • Profit Margin-17567.99%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-23.98%D
    • Total Assets YoY-24.82%E
    • Net Assets YoY-31.73%E
  • Cash ScoreC
    • Cash Flow Margin-0.57%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio14.20%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioCryst Pharmaceuticals Inc Announces Early HSR Termination for Astria Merger

    On December 3, 2025, BioCryst Pharmaceuticals Inc announced the early termination of the HSR waiting period for its Astria acquisition. Key Highlights: HSR waiting period termination clears a key merger condition.Merger with Astria expected to close in Q1 2026.Completion subject to customary closing conditions.Original SEC Filing: BIOCRYST PHARMACEUTICALS INC [ BCRX ] - 8-K - Dec. 03, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

    TradingView·
    US
    ATXS
    +0.23%
    US
    BCRX
    -0.25%
    TradingView·
    US
    ATXS
    +0.23%
    US
    BCRX
    -0.25%

    BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

    BioCryst Pharmaceuticals plans to merge with Astria Therapeutics, highlighting expected synergies and potential benefits. However, risks, uncertainties, integration challenges, expenses, and impacts on business relationships may affect the merger. Further details are available in SEC filings. This news brief was created by Public Technologies using AI and is for informational purposes only. BioCryst Pharmaceuticals published the original content via GlobeNewswire on December 03, 2025.

    Reuters·
    US
    BCRX
    -0.25%
    US
    ATXS
    +0.23%
    Reuters·
    US
    BCRX
    -0.25%
    US
    ATXS
    +0.23%

    18:59 ET Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

    Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws by Avidity Biosciences, Third Coast Bancshares, Astria Therapeutics, and FirstSun Capital Bancorp. The firm encourages shareholders to contact them to discuss their rights, as they may seek increased consideration, additional disclosures, or other relief on behalf of shareholders. The firm operates on a contingent fee basis, representing investors worldwide in securities fraud and corporate misconduct cases.

    prnewswire·
    US
    RNA
    -0.06%
    US
    ATXS
    +0.23%
    prnewswire·
    US
    RNA
    -0.06%
    US
    ATXS
    +0.23%

    15:20 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

    Monteverde & Associates PC is investigating mergers involving Third Coast Bancshares, Avidity Biosciences, Astria Therapeutics, and FirstSun Capital Bancorp. Keystone shareholders may receive shares or cash from Third Coast, Avidity shareholders $72 per share from Novartis, Astria shareholders cash and shares from BioCryst, and FirstSun shareholders will own 59.5% of the merged company with First Foundation. The firm, recognized for recovering millions for shareholders, offers free information and legal inquiries.

    prnewswire·
    US
    ATXS
    +0.23%
    US
    RNA
    -0.06%
    prnewswire·
    US
    ATXS
    +0.23%
    US
    RNA
    -0.06%

    17:31 ET KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight

    DelveInsight's report forecasts significant growth in the KLKB1 inhibitors market by 2034, driven by novel therapies targeting inflammatory, cardiovascular, and rare diseases. Key players like Intellia Therapeutics and Astria Therapeutics are advancing clinical trials for new inhibitors. The market is expanding beyond hereditary angioedema to include diabetic macular edema and other conditions, aligning with trends in personalized medicine and drug development advancements.

    prnewswire·
    US
    ATXS
    +0.23%
    US
    NTLA
    +7.51%
    prnewswire·
    US
    ATXS
    +0.23%
    US
    NTLA
    +7.51%
    © 2025 Longbridge｜Disclaimer